Schizophrenia - Pipeline Review, H1 2020

May 2020 | 383 pages | ID: S24807386E2EN
Global Markets Direct

Abstracts

Schizophrenia - Pipeline Review, H1 2020

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Schizophrenia – Pipeline Review, H1 2020, provides an overview of the Schizophrenia (Central Nervous System) pipeline landscape.

Schizophrenia is a chronic, severe, and disabling brain disorder that generally appears in late adolescence or early adulthood. Symptoms include delusions, hallucinations, disorganized speech and disorganized behavior. Risk factors include family history, age, drugs (psychoactive) and weakened immune system. Treatment includes antipsychotic medications.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Schizophrenia – Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Schizophrenia (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Schizophrenia (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Schizophrenia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 6, 1, 13, 15, 24, 3, 56 and 11 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 2, 1, 7 and 1 molecules, respectively.

Schizophrenia (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Schizophrenia (Central Nervous System).
• The pipeline guide reviews pipeline therapeutics for Schizophrenia (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Schizophrenia (Central Nervous System) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Schizophrenia (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Schizophrenia (Central Nervous System)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Schizophrenia (Central Nervous System).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Schizophrenia (Central Nervous System) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Schizophrenia - Overview
Schizophrenia - Therapeutics Development
Schizophrenia - Therapeutics Assessment
Schizophrenia - Companies Involved in Therapeutics Development
Schizophrenia - Drug Profiles
Schizophrenia - Dormant Projects
Schizophrenia - Discontinued Products
Schizophrenia - Product Development Milestones
Appendix

List Of Tables

LIST OF TABLES

Number of Products under Development for Schizophrenia, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Universities/Institutes, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Schizophrenia - Pipeline by AbbVie Inc, H1 2020
Schizophrenia - Pipeline by Acadia Pharmaceuticals Inc, H1 2020
Schizophrenia - Pipeline by Adamed Sp zoo, H1 2020
Schizophrenia - Pipeline by Adare Pharmaceuticals Inc, H1 2020
Schizophrenia - Pipeline by Adeptio Pharmaceuticals Ltd, H1 2020
Schizophrenia - Pipeline by Aequus Pharmaceuticals Inc, H1 2020
Schizophrenia - Pipeline by AgeneBio Inc, H1 2020
Schizophrenia - Pipeline by AgoneX Biopharmaceuticals Inc, H1 2020
Schizophrenia - Pipeline by Alkermes Plc, H1 2020
Schizophrenia - Pipeline by Athersys Inc, H1 2020
Schizophrenia - Pipeline by Autifony Therapeutics Ltd, H1 2020
Schizophrenia - Pipeline by Avanir Pharmaceuticals Inc, H1 2020
Schizophrenia - Pipeline by Avicanna Inc, H1 2020
Schizophrenia - Pipeline by AviMed Pharmaceuticals LLC, H1 2020
Schizophrenia - Pipeline by Avineuro Pharmaceuticals Inc, H1 2020
Schizophrenia - Pipeline by BCWorld Pharm Co Ltd, H1 2020
Schizophrenia - Dormant Projects, H1 2020
Schizophrenia - Discontinued Products, H1 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development for Schizophrenia, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Number of Products by Top 10 Targets, H1 2020
Number of Products by Stage and Top 10 Targets, H1 2020
Number of Products by Top 10 Mechanism of Actions, H1 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
Number of Products by Routes of Administration, H1 2020
Number of Products by Stage and Routes of Administration, H1 2020
Number of Products by Molecule Types, H1 2020
Number of Products by Stage and Molecule Types, H1 2020

COMPANIES MENTIONED

AbbVie Inc
Acadia Pharmaceuticals Inc
Adamed Sp zoo
Adare Pharmaceuticals Inc
Adeptio Pharmaceuticals Ltd
Aequus Pharmaceuticals Inc
AgeneBio Inc
AgoneX Biopharmaceuticals Inc
Alkermes Plc
Athersys Inc
Autifony Therapeutics Ltd
Avanir Pharmaceuticals Inc
Avicanna Inc
AviMed Pharmaceuticals LLC
Avineuro Pharmaceuticals Inc
BCWorld Pharm Co Ltd
Beloteca Inc
Biogen Inc
BioStem Technologies Inc
BioStratum Inc
BioXcel Therapeutics Inc
Boehringer Ingelheim International GmbH
Bristol-Myers Squibb Co
Cadent Therapeutics Inc
Cerevance Inc
Cerevel Therapeutics LLC
Concert Pharmaceuticals Inc
Curemark LLC
CuroNZ Ltd
Daewoong Pharmaceutical Co Ltd
Daya Drug Discoveries Inc
Delpor Inc
Denovo Biopharma LLC
Echo Pharmaceuticals BV
Enterin Inc
F. Hoffmann-La Roche Ltd
Fabre-Kramer Pharmaceuticals Inc
Gabather AB
Genentech Inc
GlaxoSmithKline Plc
GP Pharm SA
GW Pharmaceuticals Plc
H. Lundbeck AS
Impel NeuroPharma Inc
Indivior Plc
IntelGenx Corp
Intra-Cellular Therapies Inc
INVENT Pharmaceuticals Inc
IRLAB Therapeutics AB
Jiangsu Nhwa Pharmaceutical Co Ltd
Johnson & Johnson
Karuna Therapeutics Inc
Laboratorios Farmaceuticos Rovi SA
Lb Pharmaceuticals Inc
Lead Discovery Center GmbH
Lohocla Research Corp
Luye Pharma Group Ltd
Lyndra Inc
Mapi Pharma Ltd
MedinCell SA
Mental-Heal Ltd
Merck & Co Inc
Mitsubishi Tanabe Pharma Corp
Neurocea Pharmaceuticals
Neurocrine Biosciences Inc
NeurOp Inc
NeuroSolis Inc
Newron Pharmaceuticals SpA
Omeros Corp
Otsuka Holdings Co Ltd
Otsuka Pharmaceutical Co Ltd
OWP Pharmaceuticals Inc
Pfizer Inc
Ra Pharmaceuticals Inc
Reviva Pharmaceuticals Inc
Richter Gedeon Nyrt
Schrodinger LLC
Sichuan Kelun Pharmaceutical Co Ltd
Siragen Pharmaceuticals Inc
SkySea Pharmaceutical Inc
Sosei Heptares
Sumitomo Dainippon Pharma Co Ltd
Sunovion Pharmaceuticals Inc
SyneuRx International Corp
Taho Pharmaceuticals Ltd
Taisho Pharmaceutical Holdings Co Ltd
Takeda Pharmaceutical Co Ltd
Terran Biosciences Inc
Teva Pharmaceutical Industries Ltd
Vanda Pharmaceuticals Inc
Vitality Biopharma Inc
Zysis Ltd